title: [A case report--TS-1/CDDP combined chemotherapy found effective for metastatic recurrence after operation for colon cancer].
abstract: A 68-year-old male with a history of gastric resection for gastric cancer underwent resection of the sigmoid colon for a sigmoid colon cancer in February, 2000. The cancer was classified as stage III b. After operation, l-LV + 5-FU therapy was administered, but metastases to the abdominal wall, right inguinal lymph node and spleen developed in succession, and resection was repeated. In October 2001, 1 year and 8 months after sigmoidectomy, however, multiple metastasis to the intraperitoneal lymph node had developed. As surgery was not indicated, TS-1/CDDP combined chemotherapy was started. TS-1 80 mg/day was administered for 4 weeks, the drug was withdrawn for 2 weeks and CDDP 80 mg was injected by intravenous drip at the 8th day of TS-1 administration, which was used as one course. From the second course after inception of the administration, CA19-9 decreased, and after the third course the upper intraperitoneal metastatic lesion disappeared on CT. CR has been continued for 4 months up to the present. Our results suggest a possibility that this therapy is effective not only for gastric cancer but also for colon cancer. This therapy can be administered at home. It is considered to be a useful therapy from the viewpoint of QOL as well. The high DPD activity of the tumor may have been one reason this treatment was effective. This case also seems significant from the viewpoint of attaining individualization of the drug selection in chemotherapy.
authors.affiliation: Dept. of Surgery, National Nara Hospital.
authors.forename: Takeshi
authors.initials: T
authors.lastname: Shimizu
authors.forename: Seishiro
authors.initials: S
authors.lastname: Inaba
authors.forename: Masashi
authors.initials: M
authors.lastname: Nakata
authors.forename: Yuki
authors.initials: Y
authors.lastname: Matsushita
authors.forename: Yasunobu
authors.initials: Y
authors.lastname: Araki
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Koyama
authors.forename: Atsuhiro
authors.initials: A
authors.lastname: Ogino
authors.forename: Eiji
authors.initials: E
authors.lastname: Yamada
authors.forename: Tomohiko
authors.initials: T
authors.lastname: Matsuyama
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D012809:Colon, Sigmoid / Q000601:surgery; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D004338:Drug Combinations; D005472:Fluorouracil / Q000008:administration & dosage; D005743:Gastrectomy; D006801:Humans; D007262:Infusions, Intravenous; D002955:Leucovorin / Q000008:administration & dosage; D008207:Lymphatic Metastasis; D008297:Male; D010094:Oxonic Acid / Q000008:administration & dosage; D011725:Pyridines / Q000008:administration & dosage; D012811:Sigmoid Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery*; D013160:Splenic Neoplasms / Q000556:secondary; D013274:Stomach Neoplasms / Q000601:surgery; D005641:Tegafur / Q000008:administration & dosage
chemical_list: D004338:Drug Combinations; D011725:Pyridines; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D002945:Cisplatin; D002955:Leucovorin; D005472:Fluorouracil